Tulathromycin
Antibiotic
View Brand Names (1)Dose and dosage
2.5 mg/kg SQ (neck) as a single injection
-----
In beef and non-lactating dairy cattle, tulathromycin is indicated for the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni (Haemophilus somnus) and Mycoplasma bovis; and for the control of respiratory disease in cattle at high risk of developing BRD, associated with Mannheimia haemolytica, Pasteurella multocida and Histophilus somni (Haemophilus somnus). It is also FDA-approved for the treatment of bovine foot rot (interdigital necrobacillosis) associated with Fusobacterium necrophorum and Porphyromonas levii and for the treatment of infectious bovine keratoconjunctivitis (IBK) associated With Moraxella bovis.
In swine, tulathromycin is indicated for the treatment of swine respiratory
disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae.
Tulathromycin may prove useful as a treatment of Rhodococcus equi infections in foals and in treating various infections in small ruminants.
Tulathromycin is an antibacterial of the macrolide class of drugs. It is a 15-membered macrolide structure (gamithromycin also is a 16-member molecule) and considered a triamilide macrolide with three charged nitrogens. It is derived from azalide macrolides, such as azithromycin. Like other macrolides, it inhibits bacterial protein synthesis by binding to the ribosomal 50S subunit. It is considered bacteriostatic, but it may have bactericidal properties in vitro. Because of a positively charged molecule, it may penetrate gram-negative bacteria more easily than other macrolide antibiotics. Tulathromycin has a spectrum of activity that is limited to gram-positive bacteria and some gram-negative bacteria that cause respiratory diseases in cattle and pigs
Meat: 18 days